Skip to main content
RAPT Therapeutics, Inc. logo

RAPT Therapeutics, Inc. — Investor Relations & Filings

Ticker · RAPT ISIN · US75382E1091 LEI · 549300MB473BIU78ES48 US Manufacturing
Open in API
Filings indexed 534 across all filing types
Latest filing 2022-05-26 Declaration of Voting R…
Country US United States of America
Listing US RAPT

About RAPT Therapeutics, Inc.

https://rapt.com/

RAPT Therapeutics, Inc. is a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for patients with inflammatory and immunologic diseases. The company's scientific approach involves developing therapeutics that intelligently target key drivers of the immune system. Its pipeline includes ozureprubart (RPT904), a long-acting anti-IgE antibody being evaluated in a Phase 2b clinical trial for the treatment of food allergies.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated May 25, 2022, reporting the submission of matters to a vote of security holders at the company's 2022 annual meeting. It includes detailed voting results for director elections and ratification of the independent auditor. The content focuses on official voting results from the annual meeting, not the meeting materials or the full annual report. The document length is 3877 characters, which is relatively short but contains substantive voting data. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA).
2022-05-26 English
4 Filing
Director's Dealing
2022-05-26 English
FORM 4 SUBMISSION
Director's Dealing
2022-05-25 English
FORM 4 SUBMISSION
Director's Dealing
2022-05-25 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates the filing is about a press release announcing the initiation of a Phase 2b clinical trial by RAPT Therapeutics. There are no financial statements or detailed financial data included, and the document is relatively short (3256 characters). It primarily serves as a regulatory announcement of a corporate event rather than a financial report or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2022-05-23 English
FORM 4 SUBMISSION
Director's Dealing
2022-05-12 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.